$10 Billion Deal, page-13129

From the last Q

"The Company understands the high level of interest of shareholders in the outcomes of the completed clinical trials. Trials such as BIT225-011 that include longitudinal analyses of a multitude of immunological markers involve complex, time-consuming modeling and consultation with relevant experts. Good progress is being made and the Company looks forward to reporting results during the second quarter of 2024."

It's what I am waiting for anyway.

Although I am of course aware that "the coming weeks" was the original target about 9 months ago.

EB